WO2008016199A1 - Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound - Google Patents
Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound Download PDFInfo
- Publication number
- WO2008016199A1 WO2008016199A1 PCT/KR2006/003458 KR2006003458W WO2008016199A1 WO 2008016199 A1 WO2008016199 A1 WO 2008016199A1 KR 2006003458 W KR2006003458 W KR 2006003458W WO 2008016199 A1 WO2008016199 A1 WO 2008016199A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chiral
- set forth
- formula
- benzodioxane
- compound
- Prior art date
Links
- -1 2-hydroxymethyl-1,4-benzodioxane compound Chemical class 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 claims abstract description 29
- 150000001412 amines Chemical class 0.000 claims abstract description 16
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 15
- 238000007142 ring opening reaction Methods 0.000 claims abstract description 11
- 150000003863 ammonium salts Chemical class 0.000 claims abstract description 10
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 8
- AIIAHNREQDTRFI-UHFFFAOYSA-N oxiran-2-ylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1CO1 AIIAHNREQDTRFI-UHFFFAOYSA-N 0.000 claims abstract description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 60
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 22
- 239000011541 reaction mixture Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 15
- 239000003960 organic solvent Substances 0.000 claims description 15
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 239000012043 crude product Substances 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 6
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- OIFAHDAXIUURLN-UHFFFAOYSA-N 2-(fluoromethyl)oxirane Chemical compound FCC1CO1 OIFAHDAXIUURLN-UHFFFAOYSA-N 0.000 claims description 3
- AGIBHMPYXXPGAX-UHFFFAOYSA-N 2-(iodomethyl)oxirane Chemical compound ICC1CO1 AGIBHMPYXXPGAX-UHFFFAOYSA-N 0.000 claims description 3
- GFGQSUGZPPOCIY-UHFFFAOYSA-N 2-(oxiran-2-yl)ethanesulfonic acid Chemical compound OS(=O)(=O)CCC1CO1 GFGQSUGZPPOCIY-UHFFFAOYSA-N 0.000 claims description 3
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 3
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 3
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 claims description 3
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 claims description 3
- AIHIHVZYAAMDPM-UHFFFAOYSA-N oxiran-2-ylmethyl 3-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)OCC2OC2)=C1 AIHIHVZYAAMDPM-UHFFFAOYSA-N 0.000 claims description 3
- IBFRBNCRKBAISE-UHFFFAOYSA-N oxiran-2-ylmethyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OCC1CO1 IBFRBNCRKBAISE-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 3
- ODHXBMXNKOYIBV-UHFFFAOYSA-N triphenylamine Chemical compound C1=CC=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 ODHXBMXNKOYIBV-UHFFFAOYSA-N 0.000 claims description 3
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 229910000102 alkali metal hydride Inorganic materials 0.000 claims description 2
- 150000008046 alkali metal hydrides Chemical class 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 229910000318 alkali metal phosphate Inorganic materials 0.000 claims description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2
- 229910000316 alkaline earth metal phosphate Inorganic materials 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 2
- 230000003287 optical effect Effects 0.000 abstract description 12
- 238000007086 side reaction Methods 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000005406 washing Methods 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 9
- BRLQWZUYTZBJKN-VKHMYHEASA-N (-)-Epichlorohydrin Chemical compound ClC[C@H]1CO1 BRLQWZUYTZBJKN-VKHMYHEASA-N 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- 239000012452 mother liquor Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 229960001389 doxazosin Drugs 0.000 description 6
- 150000002924 oxiranes Chemical group 0.000 description 6
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- GWQOQQVKVOOHTI-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxin-3-ylmethanol Chemical compound C1=CC=C2OC(CO)COC2=C1 GWQOQQVKVOOHTI-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 3
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- GWQOQQVKVOOHTI-SSDOTTSWSA-N [(3r)-2,3-dihydro-1,4-benzodioxin-3-yl]methanol Chemical compound C1=CC=C2O[C@H](CO)COC2=C1 GWQOQQVKVOOHTI-SSDOTTSWSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229960000220 doxazosin mesylate Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229960005235 piperonyl butoxide Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical class CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 0 *c(c(*)c1*)c(*)c(O)c1O Chemical compound *c(c(*)c1*)c(*)c(O)c1O 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IAQQDIGGISSSQO-UHFFFAOYSA-N 2-(4-fluorophenyl)piperidine Chemical compound C1=CC(F)=CC=C1C1NCCCC1 IAQQDIGGISSSQO-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- HWIIAAVGRHKSOJ-UHFFFAOYSA-N 2-chloro-6,7-dimethoxyquinazolin-4-amine Chemical compound ClC1=NC(N)=C2C=C(OC)C(OC)=CC2=N1 HWIIAAVGRHKSOJ-UHFFFAOYSA-N 0.000 description 1
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical class OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
- FOILINVEQJRMPF-UHFFFAOYSA-M 2-hydroxypropyl(trimethyl)azanium;iodide Chemical compound [I-].CC(O)C[N+](C)(C)C FOILINVEQJRMPF-UHFFFAOYSA-M 0.000 description 1
- 238000006220 Baeyer-Villiger oxidation reaction Methods 0.000 description 1
- FSWDAHVGSJMVPV-UHFFFAOYSA-N CCCCC(C)OS(C)(=N)=O Chemical compound CCCCC(C)OS(C)(=N)=O FSWDAHVGSJMVPV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- UUZYBYIOAZTMGC-UHFFFAOYSA-M benzyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CC1=CC=CC=C1 UUZYBYIOAZTMGC-UHFFFAOYSA-M 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- ZMCUDHNSHCRDBT-UHFFFAOYSA-M caesium bicarbonate Chemical compound [Cs+].OC([O-])=O ZMCUDHNSHCRDBT-UHFFFAOYSA-M 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229940115457 cetyldimethylethylammonium bromide Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VUFOSBDICLTFMS-UHFFFAOYSA-M ethyl-hexadecyl-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)CC VUFOSBDICLTFMS-UHFFFAOYSA-M 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910001386 lithium phosphate Inorganic materials 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- PGIGXJYEXSOUNZ-UHFFFAOYSA-N oxiran-2-ylmethyl benzenesulfonate Chemical compound C=1C=CC=CC=1S(=O)(=O)OCC1CO1 PGIGXJYEXSOUNZ-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical class OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CPWJKGIJFGMVPL-UHFFFAOYSA-K tricesium;phosphate Chemical compound [Cs+].[Cs+].[Cs+].[O-]P([O-])([O-])=O CPWJKGIJFGMVPL-UHFFFAOYSA-K 0.000 description 1
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 1
- SZEMGTQCPRNXEG-UHFFFAOYSA-M trimethyl(octadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C SZEMGTQCPRNXEG-UHFFFAOYSA-M 0.000 description 1
- HADKRTWCOYPCPH-UHFFFAOYSA-M trimethylphenylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C1=CC=CC=C1 HADKRTWCOYPCPH-UHFFFAOYSA-M 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to a process for the preparation of a 1,4-benzodioxane compound. More particularly, the present invention relates to a process for the preparation of a chiral 2-hydroxymethyl- 1,4-benzodioxane compound.
- 1,4-Benzodioxane and its derivatives are useful intermediates for the synthesis of ⁇ - or ⁇ - adrenoceptor antagonist, a psychoneurotic drug.
- 2-hydroxymethyl- 1,4-benzodioxane is useful in the synthesis of doxazosin.
- Doxazosin is a compound useful for the treatment of hypertension (U.S. Patent No. 4,188,390), which is typically sold in a form of ( ⁇ )-doxazosin mesylate (Pfizer, trademark name "Cardular").
- Doxazosin has one chiral center and can be present in either (R)-isomer or (S)
- (S)-isomer is known to be more effective in the treatment of hypertension compared with the racemate or the (R)-isomer, because of fewer side effects such as lethargy, dizziness, etc. (U.S. Patent No. 5,510,352).
- (S )-Doxazosin can be easily prepared from (R) -2-hydroxymethyl- 1,4-benzodioxane as the starting material.
- (R) -2-hydroxymethyl- 1,4-benzodioxane is oxidized to provide (S)-l,4-benzodioxane-2-carboxylic acid, which is reacted with piperazine to provide (S)-/V-((l,4-benzodioxane)-2-carbonyl)piperazine. Thereafter, the obtained product is reacted with 4-amino-2-chloro-6,7-dimethoxyquinazoline to obtain (S )-doxazosin or its acid additive salt. If necessary, (S)-doxazosin or its acid additive salt may be reacted with methanesulfonic acid to prepare (S)-doxazosin mesylate.
- Such a chiral drug needs to be prepared in high optical purity to exhibit superior efficacy.
- the starting material 2-hydroxymethyl- 1,4-benzodioxane or its derivative has to be prepared in high purity.
- the following methods were known for preparing racemic or chiral 1,4-benzodioxane compound.
- the compound was prepared by reacting a catechol derivative with racemic epi- halohydrin in the presence of an inorganic strong base (sodium hydride, sodium butoxide or lithium amide) to result in in-situ epoxide ring opening and cyclization (U.S. Patent No. 4,595,767), or by reacting a catechol derivative with chiral glycidyl nosylate in the presence of a fluoride salt or in combination with a salt of an alkali/ alkaline earth metal (Japanese Laid-Open Patent No. 2001-316385).
- the former has low selective due to the use of a strong base and racemization occurs during the reaction.
- 1,4-benzodioxane or its derivatives was known to be prepared after selectively protection of one of two hydroxyl groups of the catechol.
- a method of preparing a chiral 1,4-benzodioxane derivative comprising reacting a mono-protected catechol derivative with a chiral glycidyl derivative or a chiral solketal derivative in the presence of potassium carbonate and a catalytic amount of tetrabutylammonium hydrosulfonate, followed by deprotection and cyclization (U.S. Patent No. 5,948,909; Tetrahedron Lett. 1988, vol. 29, p3671).
- the chiral glycidyl derivative and the chiral solketal derivative are expensive compounds and the final product, chiral 1,4-benzodioxane derivative, has an optical purity of no more than 98%, which is not sufficient to be used as an intermediate for the preparation of chiral drugs.
- An object of the present invention is to provide a process for the preparation of a chiral 1,4-benzodioxane compound having a high optical purity of 99% or more in an economic manner. According to the present invention, there is provided a process for preparing the 1,4-benzodioxane compound, wherein the chirality of the starting material is retained and the targeted 1,4-benzodioxane compound is prepared in an optical purity of 99%ee or more.
- a process for the preparation of 2-hydroxymethyl- 1,4-benzodioxane compound having formula 1 which comprises the steps of: a) reacting an epoxide compound of formula 2 with a catechol compound of formula 3 in a presence of a tertiary organic amine or its ammonium salt to carry out a ring opening reaction of the epoxide compound, followed by collecting a ring-opened product from a reaction mixture; and b) treating the ring-opened product with an inorganic base to carry out a cyclization reaction of the ring-opened product, followed by recovering the targeted product 2-hydroxymethyl- 1,4-benzodioxane of formula 1 from a reaction mixture:
- R , R , R and R are each independently hydrogen, halogen, nitro, cyano, formyl, (C -C ) alkyl, (C -C ) alkoxy, (C -C ) alkoxycarbonyl, (C -C ) alkylcarbonyloxy, (C -C ) haloalkyl, N,N-di-(C -C )
- epihalohydrin examples include chiral epifluorohydrin, chiral epichlorohydrin, chiral epibromohydrin and chiral epiiodohydrin and examples of the glycidyl sulfonate includes chiral glycidylmethanesulfonate, chiral glycidyl-/? - toluenesulfonate, chiral glycidyl-m-nitrobenzenesulfonate, chiral glycidyl-/?
- R N (wherein R , R and R are each independently C -C alkyl, C -C alkenyl or
- step a) is performed in a water-immiscible organic solvent and the step b) is performed in a water-miscible organic solvent.
- the organic solvent of the step a) is ethyl acetate and the organic solvent of the step b) is C -C alcohol.
- the optical purity of the starting material is retained throughout the reactions, thereby producing the 2-hydroxymethyl-l,4-benzodioxane compound of formula 1 in high optical purity of 99%ee or more. Further, the ring-opened intermediate can be subjected to the cy- clization reaction as a crude product such that the overall yield can be improved.
- the present invention relates to a process for the preparation of
- R , R , R and R are each independently hydrogen, halogen, nitro, cyano, formyl, (C -C ) alkyl, (C -C ) alkoxy, (C -C ) alkoxycarbonyl, (C -C ) alkylcarbonyloxy, (C -C ) haloalkyl, N,N-di-(C -C ) alkylamino, (C -C ) alkylcarbonyl, (C -C ) alkoxycarbonyloxy, C -C aromatic hydrocarbon, C -C aromatic hydrocarbon substituted with halogen, or C -C aromatic
- R is C -C alkyl group, C -C aryl group or C -C aryl group substituted
- the ring opening reaction of the epoxide compound of formula 2 by the catechol compound of formula 3 in the presence of a tertiary organic amine or its an ammonium salt and the cyclization reaction of the ring- opened product by an inorganic base are carried out sequentially .
- Preferred examples of the epoxide compound of formula 2 are chiral epihalohydrin and chiral glycidyl sulfonate.
- chiral epihalohydrin chiral epifluorohydrin, chiral epichlorohydrin, chiral epibromohydrin or chiral epiiodohydrin can be used.
- chiral glycidyl sulfonate chiral glycidylmethanesulfonate, chiral glycidyl-/?
- catechol compound of formula 3 is catechol, in which all the sub- stituents R , R , R and R are hydrogen.
- the epoxide ring opening reaction is carried out in the presence of a tertiary organic amine or an ammonium salt thereof.
- An aliphatic amine represented by R R R N (wherein R , R and R are each independently C -C alkyl, C -C alkenyl or benzyl) or a C -C heteroaromatic organic amine can be used.
- R R R N an aliphatic amine represented by R R R R N (wherein R , R and R are each independently C -C alkyl, C -C alkenyl or benzyl) or a C -C heteroaromatic organic amine can be used.
- the organic amine may be used in a form of an ammonium salt.
- ammonium salt include benzyltrimethy- lammonium chloride, diallyldimethylammonium chloride, benzyltrimethylammonium bromide, n-octyltrimethylammonium bromide, stearyltrimethylammonium bromide, cetyldimethylethylammonium bromide, tetra-n-butylammonium iodide, ⁇ - methylcholine iodide, tetra-n-butylammonium hydrogen sulfate and phenyltrimethy- lammonium hydroxide.
- the tertiary organic amine or an ammonium salt thereof is preferable used in a range of 0.01-1.00 equivalent based on the epoxide compound of formula 2. More preferably, it is used in a range of 0.1-0.2 equivalent.
- the epoxide ring opening reaction is performed in an organic solvent.
- Organic solvent such as alcohol, tetrahydrofuran, dioxane, acetone, JV,./V-dimethylformaldehyde, dimethyl sulfoxide, aromatic hydrocarbon, ether, ester, C -C halogenated hydrocarbon, etc. may be used.
- Preferable is a water- immiscible organic solvent.
- Particularly preferable is ethyl acetate.
- the organic solvent is used in 0.5-10 times, preferably 1.5 times, based on the volume of the epoxide compound of formula 2.
- the epoxide ring opening reaction is carried out at 0-80 0 C, preferably at 20-45 0 C.
- the ring-opened product represented by formula 4 is preferably obtained.
- the product may also be present in a form of epoxide.
- the cyclization reaction is carried out.
- the cyclization is performed in the presence of an inorganic base.
- an inorganic base As a base used in the cyclization reaction, alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal hydride, alkali metal alkoxide, alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, alkali metal phosphate and alkaline earth metal phosphate can be mentioned.
- Preferable is sodium hydroxide.
- the base is added as dissolved in water.
- a water- miscible organic solvent such as C -C alcohol such as methanol, ethanol, propanol, isopropanol or butanol, tetrahydrofuran, acetonitrile, JV,./V-dimethylformamide and dimethyl sulfoxide may be used.
- C -C alcohol such as methanol, ethanol, propanol, isopropanol or butanol, tetrahydrofuran, acetonitrile, JV,./V-dimethylformamide and dimethyl sulfoxide
- methanol or ethanol ethanol
- Most preferable is methanol.
- the solvent is used in 1/20-10 equivalents, preferably 1/10-1 equivalent, based on the base solution.
- the resultant crude product was dissolved into 23 mL of methanol and 233 niL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise to the solution at O 0 C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After successive washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 12.124 g (68%, 99.4%ee) of (R)-2-hydroxymethyl-l,4-benzodioxane was obtained.
- the resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 m NaOH was added dropwise at O 0 C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 9.551 g (53 %, 99.3 %ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
- Example 7 [64] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 niL of ethyl acetate and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 6.008 g (0.0216 mole, 0.2 eq) of tetrabutylammonium chloride was added to the solution and the reaction solution was stirred at 4O 0 C for 3 days. The solvent was removed from the reaction mixture under reduced pressure.
- the resultant crude product was dissolved into 23 mL of methanol and 4320 mL (8.6468 mole, 4.0 eq) of 2 M NaOH was added dropwise at O 0 C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 223.35 g (62%, 99.4%ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
Abstract
The present invention relates to a process for the preparation of chiral 2-hydroxymethyl-l,4-benzodioxane compound. The method in accordance with the present invention comprises the steps of reacting chiral epihalohydrin or chiral glycidyl sulfonate with catechol or its derivative in a presence of a tertiary organic amine or its ammonium salt to carry out an ring opening reaction of the epoxide compound and treating the ring-opened product with an inorganic base to carry out a cyclization reaction of the ring-opened product to prepare the targeted 2-hydroxymethyl-l,4-benzodioxane. The method of the present invention provides the chiral 2-hydroxymethyl-l,4-benzodioxane compound in high optical purity and with improved yield due to reduced side reactions.
Description
Description
PROCESS FOR THE PREPARATION OF CHIRAL 2-HYDROXYMETHYL-l,4-BENZODIOXANE COMPOUND
Technical Field
[1] The present invention relates to a process for the preparation of a 1,4-benzodioxane compound. More particularly, the present invention relates to a process for the preparation of a chiral 2-hydroxymethyl- 1,4-benzodioxane compound. Background Art
[2] 1,4-Benzodioxane and its derivatives are useful intermediates for the synthesis of α- or β- adrenoceptor antagonist, a psychoneurotic drug. Especially, 2-hydroxymethyl- 1,4-benzodioxane is useful in the synthesis of doxazosin. Doxazosin is a compound useful for the treatment of hypertension (U.S. Patent No. 4,188,390), which is typically sold in a form of (±)-doxazosin mesylate (Pfizer, trademark name "Cardular").
[3] Doxazosin has one chiral center and can be present in either (R)-isomer or (S
)-isomer. Of the two stereoisomers, the (S)-isomer is known to be more effective in the treatment of hypertension compared with the racemate or the (R)-isomer, because of fewer side effects such as lethargy, dizziness, etc. (U.S. Patent No. 5,510,352). (S )-Doxazosin can be easily prepared from (R) -2-hydroxymethyl- 1,4-benzodioxane as the starting material. Specifically, (R) -2-hydroxymethyl- 1,4-benzodioxane is oxidized to provide (S)-l,4-benzodioxane-2-carboxylic acid, which is reacted with piperazine to provide (S)-/V-((l,4-benzodioxane)-2-carbonyl)piperazine. Thereafter, the obtained product is reacted with 4-amino-2-chloro-6,7-dimethoxyquinazoline to obtain (S )-doxazosin or its acid additive salt. If necessary, (S)-doxazosin or its acid additive salt may be reacted with methanesulfonic acid to prepare (S)-doxazosin mesylate.
[4] Such a chiral drug needs to be prepared in high optical purity to exhibit superior efficacy. In order to produce a drug with high optical purity, the starting material 2-hydroxymethyl- 1,4-benzodioxane or its derivative has to be prepared in high purity. The following methods were known for preparing racemic or chiral 1,4-benzodioxane compound.
[5] The compound was prepared by reacting a catechol derivative with racemic epi- halohydrin in the presence of an inorganic strong base (sodium hydride, sodium butoxide or lithium amide) to result in in-situ epoxide ring opening and cyclization (U.S. Patent No. 4,595,767), or by reacting a catechol derivative with chiral glycidyl nosylate in the presence of a fluoride salt or in combination with a salt of an alkali/ alkaline earth metal (Japanese Laid-Open Patent No. 2001-316385). The former has
low selective due to the use of a strong base and racemization occurs during the reaction. Accordingly, while the method is useful for the preparation of racemates, it is not adequate for the preparation of the chiral 1,4-benzodioxane compound in high optical purity. The latter suffers from low price competitiveness because expensive reagent such as cesium fluoride has to be used. Especially, when applied to mass production, the fluorine-containing wastes are deleterious to the environment and increase the treatment cost.
[6] 1,4-benzodioxane or its derivatives was known to be prepared after selectively protection of one of two hydroxyl groups of the catechol. For example, there was reported a method of preparing a chiral 1,4-benzodioxane derivative, comprising reacting a mono-protected catechol derivative with a chiral glycidyl derivative or a chiral solketal derivative in the presence of potassium carbonate and a catalytic amount of tetrabutylammonium hydrosulfonate, followed by deprotection and cyclization (U.S. Patent No. 5,948,909; Tetrahedron Lett. 1988, vol. 29, p3671). However, the chiral glycidyl derivative and the chiral solketal derivative are expensive compounds and the final product, chiral 1,4-benzodioxane derivative, has an optical purity of no more than 98%, which is not sufficient to be used as an intermediate for the preparation of chiral drugs.
[7] There was reported a method of preparing a 1,4-benzodioxane derivative, comprising reacting a catechol derivative protected with benzyl with a chiral 3-halo-l,2-propanediol in the presence of sodium hydride, followed by the reaction with dimethyl carbonate to provide a carbonate compound, removing the benzyl group using a Pd/C catalyst and performing cyclization in the presence of sodium hydroxide (Korean Patent No. 504,522 d). As an similar method, there was also reported a process of preparing a 1,4-benzodioxane derivative, comprising reacting a protected catechol derivative with a chiral 3-halo-l,2-propanediol in the presence of sodium hydride, reacting the obtained compound with a benzenesulfonyl chloride derivative and performing cyclization using sodium hydride (European Patent No. 1,553,095). But, these methods require the protected catechol as a starting material, so protection and deprotection reaction are essentially required. As thus, the reaction procedures become complicated. Further, they are uneconomical due to the use of an expensive chiral 3-chloro-l,2-propanediol.
[8] Alternative was an enzymatic method that selectively separates the (S
)- 1,4-benzodioxane derivative from racemic 1,4-benzodioxane by a lipase catalyst in vinyl acetate as a solvent (Tetrahedron: Asymmetry, 1993, vol. 4, p339). The method provides the (S)- 1,4-benzodioxane derivative in high optical purity of 99%ee or more. However, the method was industrially inapplicable due to low productivity.
[9] Besides, there was known a method of preparing the 1,4-benzodioxane derivative,
comprising reacting a salicylaldehyde derivative or a 2-hydroxy acetophenone derivative with epihalohydrin, performing Baeyer-Villiger reaction using m - chloroperoxybenzoic acid and performing cyclization using potassium hydroxide or alkali metal carbonate (Bioorg. Med. Chem. Lett. 2001, vol. 11, p. 2783; European Patent No. 520,674; and European Patent No. 498,770). However, the method is uneconomical because expensive m-chloroperoxybenzoic acid is used and the resultant 1,4-benzodioxane has a low optical purity of no more than 93%ee. Disclosure of Invention Technical Problem
[10] An object of the present invention is to provide a process for the preparation of a chiral 1,4-benzodioxane compound having a high optical purity of 99% or more in an economic manner. According to the present invention, there is provided a process for preparing the 1,4-benzodioxane compound, wherein the chirality of the starting material is retained and the targeted 1,4-benzodioxane compound is prepared in an optical purity of 99%ee or more. Technical Solution
[11] According to a preferred embodiment of the present invention, there is provided a process for the preparation of 2-hydroxymethyl- 1,4-benzodioxane compound having formula 1, which comprises the steps of: a) reacting an epoxide compound of formula 2 with a catechol compound of formula 3 in a presence of a tertiary organic amine or its ammonium salt to carry out a ring opening reaction of the epoxide compound, followed by collecting a ring-opened product from a reaction mixture; and b) treating the ring-opened product with an inorganic base to carry out a cyclization reaction of the ring-opened product, followed by recovering the targeted product 2-hydroxymethyl- 1,4-benzodioxane of formula 1 from a reaction mixture:
[12] Formula 1
[13]
[14] Formula 2
[16] Formula 3
[17]
[18] wherein, * represents a chiral center, R , R , R and R are each independently hydrogen, halogen, nitro, cyano, formyl, (C -C ) alkyl, (C -C ) alkoxy, (C -C ) alkoxycarbonyl, (C -C ) alkylcarbonyloxy, (C -C ) haloalkyl, N,N-di-(C -C )
1 4 1 4 1 4 alkylamino, (C -C ) alkylcarbonyl, (C -C ) alkoxycarbonyloxy, C -C aromatic hydrocarbon, C -C aromatic hydrocarbon substituted with halogen, or C -C aromatic
6 10 J to 6 10 hydrocarbon substituted with (C -C ) alkyl, or two neighboring substituents of R , R ,
1 4 1 2
R and R taken together form a methylenedioxy group or a benzene ring, and X
3 4 represents a leaving group.
[19] According to more preferred embodiment of the present invention, there is provided a process for the preparation of 2-hydroxymethyl-l,4-benzodioxane compound, wherein the ring-opened product of the step a) is collected as a crude product and subjected to the next cyclization reaction.
[20] According to another preferred embodiment of the present invention, there is provided a process for the preparation of 2-hydroxymethyl-l,4-benzodioxane compound, wherein the ring-opened product has formula 4:
[21] Formula 4 [22]
[23] wherein, * represents a chiral center and R , R , R , R and X are the same as defined in the above. [24] According to further another preferred embodiment of the present invention, there is provided a process for the preparation of 2-hydroxymethyl-l,4-benzodioxane compound, wherein the epoxide compound of formula 2 is epihalohydrin or glycidyl sulfonate. Examples of the epihalohydrin include chiral epifluorohydrin, chiral epichlorohydrin, chiral epibromohydrin and chiral epiiodohydrin and examples of the glycidyl sulfonate includes chiral glycidylmethanesulfonate, chiral glycidyl-/? - toluenesulfonate, chiral glycidyl-m-nitrobenzenesulfonate, chiral glycidyl-/? -
nitrobenzenesulfonate, chiral glycidyltrifluoromethanesulfonate and chiral glycidyl- benzenesulfonate. Most preferable is chiral epichlorohydrin.
[25] According to still further another preferred embodiment of the present invention, there is provided a process for the preparation of 2-hydroxymethyl-l,4-benzodioxane compound, wherein the tertiary organic amine is an aliphatic amine represented by R i R
R N (wherein R , R and R are each independently C -C alkyl, C -C alkenyl or
2 3 1 2 3 r ■7 1 6 -7 2 16 J benzyl) or a C -C heteroaromatic organic amine. As a specific example, trimethylamine, triethylamine, tripropylamine, dimethylethylamine, tributylamine, N - methylpyrrolidine, JV-methylpiperidine, diisopropylethylamine, triphenylamine, pyridine, pyrrole or lutidine can be mentioned. Most preferable is pyridine. [26] According to yet another preferred embodiment of the present invention, there is provided a process for the preparation of 2-hydroxymethyl-l,4-benzodioxane compound, wherein the step a) is performed in a water-immiscible organic solvent and the step b) is performed in a water-miscible organic solvent. Preferably, the organic solvent of the step a) is ethyl acetate and the organic solvent of the step b) is C -C alcohol.
Advantageous Effects
[27] According to the method of the present invention, the optical purity of the starting material is retained throughout the reactions, thereby producing the 2-hydroxymethyl-l,4-benzodioxane compound of formula 1 in high optical purity of 99%ee or more. Further, the ring-opened intermediate can be subjected to the cy- clization reaction as a crude product such that the overall yield can be improved. Mode for the Invention
[28] The present invention relates to a process for the preparation of
2-hydroxymethyl-l,4-benzodioxane compound having formula 1, which comprises the steps of:
[29] a) reacting an epoxide compound of formula 2 with a catechol compound of formula 3 in a presence of a tertiary organic amine or its ammonium salt to carry out a ring opening reaction of the epoxide compound, followed by collecting a ring-opened product from a reaction mixture; and
[30] b) treating the ring-opened product with an inorganic base to carry out a cyclization reaction of the ring-opened product, followed by recovering the targeted product 2-hydroxymethyl-l,4-benzodioxane of formula 1 from a reaction mixture:
[31] Formula 1
O
X
[35] Formula 3 [36]
[37] wherein, * represents a chiral center, R , R , R and R are each independently hydrogen, halogen, nitro, cyano, formyl, (C -C ) alkyl, (C -C ) alkoxy, (C -C ) alkoxycarbonyl, (C -C ) alkylcarbonyloxy, (C -C ) haloalkyl, N,N-di-(C -C ) alkylamino, (C -C ) alkylcarbonyl, (C -C ) alkoxycarbonyloxy, C -C aromatic hydrocarbon, C -C aromatic hydrocarbon substituted with halogen, or C -C aromatic
6 10 J & 6 10 hydrocarbon substituted with (C -C ) alkyl, or two neighboring substituents of R , R , R and R taken together form a methylenedioxy group or a benzene ring, and X represents a leaving group, preferably halogen or sulfonate represented by
, wherein R is C -C alkyl group, C -C aryl group or C -C aryl group substituted
5 1 10 6 10 6 10 with nitro group, methyl group, ethyl group, fluoro group or chloro group.
[38] In accordance with the present invention, the ring opening reaction of the epoxide compound of formula 2 by the catechol compound of formula 3 in the presence of a tertiary organic amine or its an ammonium salt and the cyclization reaction of the ring- opened product by an inorganic base are carried out sequentially .
[39] Preferred examples of the epoxide compound of formula 2 are chiral epihalohydrin and chiral glycidyl sulfonate. As a chiral epihalohydrin, chiral epifluorohydrin, chiral epichlorohydrin, chiral epibromohydrin or chiral epiiodohydrin can be used. And, as a chiral glycidyl sulfonate, chiral glycidylmethanesulfonate, chiral glycidyl-/? -
toluenesulfonate, chiral glycidyl-m-nitrobenzenesulfonate, chiral glycidyl-/? - nitrobenzenesulfonate, chiral glycidyltrifluoromethanesulfonate or chiral glycidylben- zenesulfonate can be used. Most preferable is chiral epichlorohydrin. A preferred example of the catechol compound of formula 3 is catechol, in which all the sub- stituents R , R , R and R are hydrogen.
[40] The epoxide ring opening reaction is carried out in the presence of a tertiary organic amine or an ammonium salt thereof. An aliphatic amine represented by R R R N (wherein R , R and R are each independently C -C alkyl, C -C alkenyl or benzyl) or a C -C heteroaromatic organic amine can be used. As a specific example, trimethylamine, triethylamine, tripropylamine, dimethylethylamine, tributylamine, N - methylpyrrolidine, JV-methylpiperidine, diisopropylethylamine, triphenylamine, pyridine, pyrrole or lutidine can be mentioned. The organic amine may be used in a form of an ammonium salt. Examples of the ammonium salt include benzyltrimethy- lammonium chloride, diallyldimethylammonium chloride, benzyltrimethylammonium bromide, n-octyltrimethylammonium bromide, stearyltrimethylammonium bromide, cetyldimethylethylammonium bromide, tetra-n-butylammonium iodide, β- methylcholine iodide, tetra-n-butylammonium hydrogen sulfate and phenyltrimethy- lammonium hydroxide. Test results on various organic amines and their ammonium salts showed that pyridine is the most preferable. The tertiary organic amine or an ammonium salt thereof is preferable used in a range of 0.01-1.00 equivalent based on the epoxide compound of formula 2. More preferably, it is used in a range of 0.1-0.2 equivalent.
[41] The epoxide ring opening reaction is performed in an organic solvent. The choice of the adequate organic solvent is well known to a person of ordinary skill to which the present invention pertains. Organic solvent such as alcohol, tetrahydrofuran, dioxane, acetone, JV,./V-dimethylformaldehyde, dimethyl sulfoxide, aromatic hydrocarbon, ether, ester, C -C halogenated hydrocarbon, etc. may be used. Preferable is a water- immiscible organic solvent. Particularly preferable is ethyl acetate. The organic solvent is used in 0.5-10 times, preferably 1.5 times, based on the volume of the epoxide compound of formula 2. The epoxide ring opening reaction is carried out at 0-800C, preferably at 20-450C.
[42] From the ring opening reaction, the ring-opened product represented by formula 4 is preferably obtained. The product may also be present in a form of epoxide.
[43] Formula 4
[45] wherein, * represents a chiral center and R , R , R , R and X are the same as defined in the above.
[46] After the epoxide ring opening reaction, the cyclization reaction is carried out. The cyclization is performed in the presence of an inorganic base. As a base used in the cyclization reaction, alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal hydride, alkali metal alkoxide, alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, alkali metal phosphate and alkaline earth metal phosphate can be mentioned. Specifically, sodium hydroxide, potassium hydroxide, lithium hydroxide, cesium hydroxide, calcium hydroxide, sodium methoxide, sodium ethoxide, sodium ?-butoxide, potassium ?-butoxide, lithium carbonate, sodium carbonate, potassium carbonate, cesium carbonate, magnesium carbonate, calcium carbonate, lithium bicarbonate, sodium bicarbonate, potassium bicarbonate, cesium bicarbonate, lithium phosphate, sodium phosphate, potassium phosphate, cesium phosphate, magnesium phosphate and calcium phosphate may be used. Preferable is sodium hydroxide. The base is added as dissolved in water.
[47] As an organic solvent used in the cyclization reaction of the step b), a water- miscible organic solvent such as C -C alcohol such as methanol, ethanol, propanol, isopropanol or butanol, tetrahydrofuran, acetonitrile, JV,./V-dimethylformamide and dimethyl sulfoxide may be used. Preferable is methanol or ethanol. Most preferable is methanol. The solvent is used in 1/20-10 equivalents, preferably 1/10-1 equivalent, based on the base solution.
[48] The present invention will be more fully illustrated referring to the following examples, but it should not be construed that the scope of the present invention is limited thereto.
[49] EXAMPLES
[50] Example 1
[51] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of ethyl acetate, and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 1.74 mL (0.0216 mole, 0.2 eq) of pyridine was added to the solution and the reaction solut ion was stirred at 4O0C for 2 days. To the reaction mixture, 2 M sulfuric acid solution was added to adjust the pH to 4-5. After washing with water, the solvent was removed under reduced pressure. The resultant crude product was dissolved into 23 mL of
methanol and 233 niL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise to the solution at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After successive washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 12.124 g (68%, 99.4%ee) of (R)-2-hydroxymethyl-l,4-benzodioxane was obtained.
[52] The optical purity (%ee) of 2-hydroxymethyl-l,4-benzodioxane was measured by high performance liquid chromatography. Knauer's Eurocel OD column (0.46 cm x 25 cm) was used and 90:10 (v/v) n-hexane/isopropanol mixed solvent was flown at a rate of 1.0 mL/min. HPLC spectrum was obtained at 254 nm. The (R)-isomer was detected at 7.51 minutes and the (S)-isomer was detected at 8.07 minutes.
[53] Example 2
[54] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of acetone and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 1.74 mL (0.0216 mole, 0.2 eq) of pyridine was added to the solution and the reaction solution was stirred at 4O0C for 2 days. The solvent was removed from the reaction mixture under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After successive washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 11.045 g (61%, 99.2%ee) of ( /?)-2-hydroxymethyl-l,4-benzodioxane was obtained.
[55] Example 3
[56] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of ethyl acetate and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 0.87 mL (0.0108 mole, 0.10 eq) of pyridine was added to the solution and the reaction solution was stirred at 4O0C for 3 days. 2 M sulfuric acid was added to the reaction mixture to adjust the pH to 4-5. After washing with water, the solvent was removed under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 m NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 9.551 g (53 %, 99.3 %ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
[57] Example 4
[58] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of
ethyl acetate and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 0.87 rnL (0.0108 mole, 0.10 eq) of pyridine was added to the solution and the reaction solution was stirred at room temperature for 4.5 days. 2 M sulfuric acid was added to the reaction mixture to adjust the pH to 4-5. After washing with water, the solvent was removed under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After successive washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 9.542 g (53%, 99.4%ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
[59] Example 5
[60] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of ethyl acetate and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 3.01 mL (0.0216 mole, 0.2 eq) of triethylamine was added to the solution and the reaction solution was stirred at 4O0C for 3 days. 2 M sulfuric acid was added to the reaction mixture to adjust the pH to 4-5. After washing with water, the solvent was removed under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 9.873 g (55%, 99.4%ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
[61] Example 6
[62] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of ethyl acetate and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 1.15 mL (0.0108 mole, 0.1 eq) of triethylamine was added to the solution and the reaction solution was stirred at 4O0C for 4.5 days. 2 M sulfuric acid was added to the reaction mixture to adjust the pH to 4-5. After washing with water, the solvent was removed under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 6.138 g (34%, 99.2%ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
[63] Example 7
[64] 10 g (0.1081 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 niL of ethyl acetate and 21.436 g (0.1946 mole, 1.8 eq) of catechol was added thereto. 6.008 g (0.0216 mole, 0.2 eq) of tetrabutylammonium chloride was added to the solution and the reaction solution was stirred at 4O0C for 3 days. The solvent was removed from the reaction mixture under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 233 mL (0.2594 mole, 2.4 eq) of 2 M NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 7.954 g (44%, 99.2%ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
[65] Example 8
[66] 200 g (2.1617 mole, 1.0 eq) of (R)-epichlorohydrin was dissolved into 18 mL of ethyl acetate and 428.72 g (3.8911 mole, 1.8 eq) of catechol was added thereto. 34.97 mL (0.4323 mole, 0.2 eq) of pyridine was added to the solution and the reaction solution was stirred at 4O0C for 2 days. 2 M sulfuric acid was added to the reaction mixture to adjust the pH to 4-5. After washing with water, the solvent was removed under reduced pressure. The resultant crude product was dissolved into 23 mL of methanol and 4320 mL (8.6468 mole, 4.0 eq) of 2 M NaOH was added dropwise at O0C for 1.5 hours. After stirring for 2.5 hours, the reaction mixture was extracted with methylene chloride. After washing with 2 M aqueous NaOH solution and water, the extract was dried with magnesium sulfate and filtered. The solvent was removed from the mother liquor under reduced pressure. 223.35 g (62%, 99.4%ee) of (R )-2-hydroxymethyl-l,4-benzodioxane was obtained.
Claims
[1] A process for the preparation of 2-hydroxymethyl-l,4-benzodioxane compound having formula 1, which comprises the steps of: a) reacting an epoxide compound of formula 2 with a catechol compound of formula 3 in a presence of a tertiary organic amine or its ammonium salt to carry out a ring opening reaction of the epoxide compound, followed by collecting a ring-opened product from a reaction mixture; and b) treating the ring-opened product with an inorganic base to carry out a cy- clization reaction of the ring-opened product, followed by recovering the targeted product 2-hydroxymethyl-l,4-benzodioxane of formula 1 from a reaction mixture:
Formula 1
wherein, * represents a chiral center, R , R , R and R are each independently hydrogen, halogen, nitro, cyano, formyl, (C -C ) alkyl, (C -C ) alkoxy, (C -C ) alkoxycarbonyl, (C -C ) alkylcarbonyloxy, (C -C ) haloalkyl, N,N-di-(C -C )
1 4 1 4 1 4 alkylamino, (C -C ) alkylcarbonyl, (C -C ) alkoxycarbonyloxy, C -C aromatic hydrocarbon, C -C aromatic hydrocarbon substituted with halogen, or C -C aromatic hydrocarbon substituted with (C -C ) alkyl, or two neighboring sub- stituents of R , R , R and R taken together form a methylenedioxy group or a benzene ring, and X represents a leaving group.
[2] The process as set forth in claim 1, wherein the ring-opened product of the step a) is collected as a crude product and subjected to the next cyclization reaction. [3] The process as set forth in claim 1, wherein the ring-opened product has formula
4: Formula 4
1 2 3 4 defined in claim 1.
[4] The process as set forth in claim 1, wherein the epoxide compound of formula 2 is epihalohydrin or glycidyl sulfonate.
[5] The process as set forth in claim 4, wherein the epihalohydrin is selected from the group consisting of chiral epifluorohydrin, chiral epichlorohydrin, chiral epi- bromohydrin and chiral epiiodohydrin, and the glycidyl sulfonate is selected from the group consisting of chiral glycidylmethanesulfonate, chiral glycidyl-/? - toluenesulfonate, chiral glycidyl-m-nitrobenzenesulfonate, chiral glycidyl-/? - nitrobenzenesulfonate, chiral glycidyltrifluoromethanesulfonate and chiral gly- cidylbenzenesulfonate.
[6] The process as set forth in claim 4, wherein the epihalohydrin is chiral epichlorohydrin.
[7] The process as set forth in claim 1, wherein all of R , R , R and R are hydrogen.
[8] The process as set forth in claim 1, wherein the tertiary organic amine is an aliphatic amine represented by R R R N (wherein R , R and R are each inder pendently J C \ -C f, alky J l, C 2 -C 16 alkeny J l or benzy J l) or a C 4 -C 10 heteroaromatic organic amine.
[9] The process as set forth in claim 8, wherein the tertiary organic amine is trimethylamine, triethylamine, tripropylamine, dimethylethylamine, trib- utylamine, JV-methylpyrrolidine, JV-methylpiperidine, diisopropylethylamine, triphenylamine, pyridine, pyrrole or lutidine.
[10] The process as set forth in claim 9, wherein the tertiary organic amine is pyridine.
[H] The process as set forth in claim 1, wherein the epoxide compound of formula 2 is an optically active compound.
[12] The process as set forth in claim 1, wherein X is halogen or sulfonate represented by
5 1 10 6 10 6 10 methyl, ethyl, fluoro or chloro.
[13] The process as set forth in claim 1, wherein the inorganic base of step b) is alkali metal hydroxide, alkaline earth metal hydroxide, alkali metal hydride, alkali metal alkoxide, alkali metal carbonate, alkaline earth metal carbonate, alkali metal bicarbonate, alkaline earth metal bicarbonate, alkali metal phosphate or alkaline earth metal phosphate.
[14] The process as set forth in claim 13, wherein the inorganic base is sodium hydroxide.
[15] The process as set forth in claim 1, wherein the step a) is performed in a water- immiscible organic solvent and the step b) is performed in a water-miscible organic solvent.
[16] The process as set forth in claim 15, wherein the organic solvent of the step a) is ethyl acetate and the organic solvent of the step b) is C -C alcohol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006800555155A CN101501016B (en) | 2006-08-02 | 2006-08-31 | Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2006-0072945 | 2006-08-02 | ||
KR1020060072945A KR100780538B1 (en) | 2006-08-02 | 2006-08-02 | Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008016199A1 true WO2008016199A1 (en) | 2008-02-07 |
Family
ID=38997362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2006/003458 WO2008016199A1 (en) | 2006-08-02 | 2006-08-31 | Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR100780538B1 (en) |
CN (1) | CN101501016B (en) |
WO (1) | WO2008016199A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030360A1 (en) * | 1995-03-24 | 1996-10-03 | Daiso Co., Ltd. | Process for producing 1,4-benzodioxane derivatives |
US5948909A (en) * | 1996-01-25 | 1999-09-07 | Duphar International Research B.V. | Process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer |
EP1553095A1 (en) * | 2002-07-29 | 2005-07-13 | Kaneka Corporation | Process for industrially producing optically active 1,4-benzodioxane derivative |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100504522B1 (en) | 1997-05-12 | 2005-12-21 | 다이소 가부시키가이샤 | Process for producing 1,4-benzodioxane derivatives |
-
2006
- 2006-08-02 KR KR1020060072945A patent/KR100780538B1/en not_active IP Right Cessation
- 2006-08-31 CN CN2006800555155A patent/CN101501016B/en not_active Expired - Fee Related
- 2006-08-31 WO PCT/KR2006/003458 patent/WO2008016199A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996030360A1 (en) * | 1995-03-24 | 1996-10-03 | Daiso Co., Ltd. | Process for producing 1,4-benzodioxane derivatives |
US5948909A (en) * | 1996-01-25 | 1999-09-07 | Duphar International Research B.V. | Process for the stereoselective preparation of a hetero-bicyclic alcohol enantiomer |
EP1553095A1 (en) * | 2002-07-29 | 2005-07-13 | Kaneka Corporation | Process for industrially producing optically active 1,4-benzodioxane derivative |
Also Published As
Publication number | Publication date |
---|---|
CN101501016A (en) | 2009-08-05 |
CN101501016B (en) | 2012-10-24 |
KR100780538B1 (en) | 2007-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100383300B1 (en) | Preparation method of 1,4-benzodioxane derivative | |
JP5735025B2 (en) | Nebivolol intermediate | |
Somfai et al. | Asymmetric synthesis of (+)-1-deoxynojirimycin and (+)-castanospermine | |
BRPI0719264A2 (en) | NEBIVOLOL PREPARATION PROCESS | |
WO2008016199A1 (en) | Process for the preparation of chiral 2-hydroxymethyl-1,4-benzodioxane compound | |
US6057476A (en) | Process for the preparation of 3-amino-2-hydroxy-1-propyl ethers | |
US7091349B2 (en) | Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution | |
US6087512A (en) | Process for preparation of glycidyl ether | |
EP3105214B1 (en) | A new method for producing nebivolol hydrochloride of high purity | |
Martin et al. | A simple and efficient synthesis of optically pure 4-alkylisoxazolidin-4-ols | |
KR101842425B1 (en) | New process for preparing Citalopram and Escitalopram | |
JP2007297330A (en) | Method of manufacturing 2-methylglycidyl derivative | |
WO2007132990A1 (en) | Process for the preparation of chiral glycidylphthalimide in highly optical purity | |
FR2689890A1 (en) | Process for the manufacture of a benzo [b] thiophenyl-5 derivative and intermediate of manufacture | |
KR100418327B1 (en) | New aziridine derivatives and their preparation methods | |
KR100788532B1 (en) | 2,2-disubstituted 1,3-dioxolanes as antitussive agents | |
JPH0637482B2 (en) | Process for producing optically active atenolol and its intermediates | |
WO2004011451A1 (en) | Process for industrially producing optically active 1,4-benzodioxane derivative | |
JP4001388B2 (en) | Method for producing 3-amino-2-hydroxy-1-propyl ether | |
WO1995012589A1 (en) | Process for the preparation of n-4-[(substituted phenyl)alkylthienyl]-, and n-4-[(substituted phenyl)alkylfuryl]but-3-yn-2-yl]-n-hydroxyurea compounds | |
JP2001139564A (en) | Method of producing optically active oxazolidinone compound | |
JP2002293782A (en) | Method for producing 1,4-benzodioxane derivative | |
NZ223003A (en) | Process for preparing alkoxyalkylidene-hydrazinopyridazines | |
JP2005089442A (en) | New manufacturing method of 3,4-epoxybutyl 1-sulfonate compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680055515.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06798607 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06798607 Country of ref document: EP Kind code of ref document: A1 |